Advances in Personalized Medicine and Genomics for Diabetes Type-2 Management Towards Precision Health
Genomic Insights into Type-2 Diabetes
DOI:
https://doi.org/10.69750/dmls.01.06.058Keywords:
Precision Medicine, Genomics, Type 2 Diabetes Mellitus, Pharmacogenomics, Glycemic Control, Drug Metabolism, Genetic Testing, Treatment Adherence, Diabetes Complications, Personalized Therapy.Abstract
Background: Conventional approaches for diabetes type-2 management generally fail to consider genetic and environmental variations for each patient. But new developments in personalized medicine and genetics are changing our understanding and approaches for type-2 treatment.
Objective: To explore the effectiveness of a personalized medicine and genomic based interventions for glycemic level, medication compliance and complications in patients with diabetes type-2 compared to usual care.
Methodology: A Randomized Controlled Trial (RCT) study was performed on total n=400 patients with type 2 diabetes. Patients were randomly assigned to two groups; the intervention group was treated according to genomic profile while the control group was treated in a routine manner. Glycemic control (HbA1c), treatment compliance, and the rate of complications during September 2023 till June 2024 were considered as primary indicators. An independent sample t-test and a chi-square test were used to analyse the results with the help of the SPSS version 27.0. p≤0.05 was considered statistically significant.
Results: Those patients who were given individualized management had improved mean HbA1c level by 1 percent as compared to the initial level. 2% compared to 0.6% in the standard care group(p<0.01). Patients in the personalized care group had an 85% compliance to recommended treatment as opposed to the standard care group with only 65% (p<0.001). Also, the number of complications was much fewer in the personalized care group (10%) as compared to the standard care group (20%); (p= 0.02).
Conclusion: Personalized medicine and genomics-based interventions offer substantial benefits in the management of Type 2 diabetes, leading to better blood sugar control, higher treatment adherence, and fewer complications. These findings suggest that integrating genomics into diabetes care could improve health outcomes for patients.
Downloads
References
Rehman F, Hayat T, Fatima H, Shafiq M, Masood U, Batool R. Integrative Approaches in the Management of Diabetic Foot Ulcers: A Comparative Study of Conventional and Alternative Therapies: Integrative Approaches in Diabetic Foot Ulcer Therapy. DEVELOPMENTAL MEDICO-LIFE-SCIENCES. 2024;1(2):44-52.doi: 10.69750/dmls.01.02.027
Sugandh F, Chandio M, Raveena F, Kumar L, Karishma F, Khuwaja S, et al. Advances in the Management of Diabetes Mellitus: A Focus on Personalized Medicine. Cureus. 2023;15(8):e4369 7.doi:10.7759/cureus.43697
Hassan M, Awan FM, Naz A, deAndrés-Galiana EJ, Alvarez O, Cernea A, et al. Innovations in Genomics and Big Data Analytics for Personalized Medicine and Health Care: A Review. International Journal of Molecular Sciences. 2022;23(9):4645.doi: 10.3390/ijms23094645
Wang DD, Hu FB. Precision nutrition for prevention and management of type 2 diabetes. The Lancet Diabetes & Endocrinology. 2018;6(5):416-26.doi: 10.1016/S2213-8587(18)30037-8
Moore JB. From personalised nutrition to precision medicine: the rise of consumer genomics and digital health. Proceedings of the Nutrition Society. 2020;79(3):300-10.doi: 10.1017/S0029665120006977
Traversi D, Pulliero A, Izzotti A, Franchitti E, Iacoviello L, Gianfagna F, et al. Precision Medicine and Public Health: New Challenges for Effective and Sustainable Health. Journal of Personalized Medicine. 2021;11(2):135.doi: 10.3390/jpm11020135
Thomas PPM, Alshehri SM, van Kranen HJ, Ambrosino E. The Impact of Personalized Medicine of Type 2 Diabetes Mellitus in the Global Health Context. Personalized Medicine. 2016;13(4):381-93.doi: 10.2217/pme-2016-0029
Vaxillaire M, Froguel P, Bonnefond A. How Recent Advances in Genomics Improve Precision Diagnosis and Personalized Care of Maturity-Onset Diabetes of the Young. Current Diabetes Reports. 2019;19(9):79.doi: 10.1007/s11892-019-1202-x
Gloyn AL, Drucker DJ. Precision medicine in the management of type 2 diabetes. The Lancet Diabetes & Endocrinology. 2018;6(11):891-900.doi: 10.1016/S2213-8587(18)30052-4
Williams DM, Jones H, Stephens JW. Personalized Type 2 Diabetes Management: An Update on Recent Advances and Recommendations. Diabetes, Metabolic Syndrome and Obesity. 2022;15(null):281-95.doi: 10.2147/DMSO.S331654
Lin Y, Wessel J. The Continuing Evolution of Precision Health in Type 2 Diabetes: Achievements and Challenges. Current Diabetes Reports. 2019;19(4):16.doi: 10.1007/s11892-019-1137-2
Florez JC, Pearson ER. A roadmap to achieve pharmacological precision medicine in diabetes. Diabetologia. 2022;65(11):1830-8.doi: 10.1007/s00125-022-05732-3
Chen R, Snyder M. Promise of personalized omics to precision medicine. WIREs Systems Biology and Medicine. 2013;5(1):73-82.doi:10.1002/wsbm.1198
Hamid Reza Aghaei M, Mandana H, Bagher L. Path to Personalized Medicine for Type 2 Diabetes Mellitus: Reality and Hope. Acta Medica Iranica. 2017;55(3).
Prasad RB, Groop L. Precision medicine in type 2 diabetes. Journal of Internal Medicine. 2019;285(1):40-8.doi: 10.1111/joim.12859
Szczerbinski L, Florez JC. Precision medicine of obesity as an integral part of type 2 diabetes management – past, present, and future. The Lancet Diabetes & Endocrinology. 2023;11(11):861-78.doi: 10.1016/S2213-8587(23)00232-2
Seyhan AA, Carini C. Are innovation and new technologies in precision medicine paving a new era in patients centric care? Journal of Translational Medicine. 2019;17(1):114.doi: 10.1186/s12967-019-1864-9
Chung WK, Erion K, Florez JC, Hattersley AT, Hivert M-F, Lee CG, et al. Precision Medicine in Diabetes: A Consensus Report From the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2020;43(7):1617-35.doi: 10.2337/dci20-0022
Ghajari G, Bermas Y, Saremi M. The Imperative of Implementing Precision Medicine in the Context of Diabetes and Treatment. Personalized Medicine Journal. 2023;8(31):26-34.doi: 10.22034/pmj.2023.2015856.1019
Franks PW, Cefalu WT, Dennis J, Florez JC, Mathieu C, Morton RW, et al. Precision medicine for cardiometabolic disease: a framework for clinical translation. The Lancet Diabetes & Endocrinology. 2023;11(11):822-35.doi:10.1016/S2213-8587(23)00165-1
Subramanian M, Wojtusciszyn A, Favre L, Boughorbel S, Shan J, Letaief KB, et al. Precision medicine in the era of artificial intelligence: implications in chronic disease management. Journal of Translational Medicine. 2020;18 (1):472.doi: 10.1186/s12967-020-02658-5
Singh S, Sarma DK, Verma V, Nagpal R, Kumar M. Unveiling the future of metabolic medicine: omics technologies driving personalized solutions for precision treatment of metabolic disorders. Biochemical and Biophysical Research Communications. 2023;682:1-20.doi:10.1016/j.bbrc.2023.09.064
Hulsen T, Jamuar SS, Moody AR, Karnes JH, Varga O, Hedensted S, et al. From Big Data to Precision Medicine. Frontiers in Medicine. 2019;6.doi: 10.3389/fmed.2019.00034
Strianese O, Rizzo F, Ciccarelli M, Galasso G, D’Agostino Y, Salvati A, et al. Precision and Personalized Medicine: How Genomic Approach Improves the Management of Cardiovascular and Neurodegenerative Disease. Genes. 2020;11(7): 747.doi: 10.3390/genes11070747
Downloads
PlumX Metrics
Published
Issue
Section
License
Copyright (c) 2024 DEVELOPMENTAL MEDICO-LIFE-SCIENCES
This work is licensed under a Creative Commons Attribution 4.0 International License.
The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/public domain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
